StockOtters
StockOttersSupply Chain Map
WuXi Biologics (Cayman) Inc. logo

WuXi Biologics (Cayman) Inc.

2269.HK

Financial Statements

Income Statement (Annual)

Amounts in millions

2024

12/31/2024

Revenue
2,428
Cost of Revenue
1,433
Gross Profit
995
Gross Margin
41.0%
Operating Income
647
Operating Margin
26.6%
Net Income
436
Net Margin
18.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
836
EBITDA Margin
34.4%

2023

12/31/2023

Revenue
2,214
Cost of Revenue
1,327
Gross Profit
888
Gross Margin
40.1%
Operating Income
579
Operating Margin
26.1%
Net Income
442
Net Margin
20.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
715
EBITDA Margin
32.3%

2022

12/31/2022

Revenue
1,985
Cost of Revenue
1,111
Gross Profit
874
Gross Margin
44.0%
Operating Income
564
Operating Margin
28.4%
Net Income
575
Net Margin
29.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
809
EBITDA Margin
40.8%

2021

12/31/2021

Revenue
1,338
Cost of Revenue
710
Gross Profit
628
Gross Margin
46.9%
Operating Income
414
Operating Margin
31.0%
Net Income
441
Net Margin
32.9%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
587
EBITDA Margin
43.9%

2020

12/31/2020

Revenue
730
Cost of Revenue
400
Gross Profit
329
Gross Margin
45.1%
Operating Income
195
Operating Margin
26.8%
Net Income
220
Net Margin
30.1%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
300
EBITDA Margin
41.2%